TY  - RPRT
TI  - CETSA MS profiling for a comparative assessment of FDA approved antivirals repurposed for COVID-19 therapy identifies Trip13 as a Remdesivir off-target
AU  - Friman, T.
AU  - Chernobrovkin, A.
AU  - Martinez Molina, D.
AU  - Arnold, L. H.
PY  - 2020
DO  - 10.1101/2020.07.19.210492
UR  - https://www.biorxiv.org/content/10.1101/2020.07.19.210492v1
ID  - 10.1101/2020.07.19.210492
ER  -